Medpace (MEDP) vs Revvity (RVTY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Revvity (RVTY) has outperformed Medpace (MEDP) over the past year, gaining 65.8% versus a gain of 13.5%. Over five years, MEDP leads with a +222.2% price change compared with -10.4% for RVTY. Revvity is the larger company by market cap ($17.20 billion vs $17.08 billion), about 1.0 times the size, while Medpace is growing revenue faster (+20.0% vs +3.7%).
On valuation, Revvity trades at a lower forward P/E (26.2x vs 31.7x for Medpace). Revvity pays a dividend yielding 0.18%, while Medpace does not currently pay one. Medpace converts more of its revenue into profit, with a net margin of 17.8% versus 8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MEDP | RVTY |
|---|---|---|
| Share price | $612.05 | $154.18 |
| Market cap | $17.08B | $17.20B |
| 1-day change | +1.55% | +1.33% |
| YTD return | +7.31% | +57.27% |
| 1-year return | +13.50% | +65.81% |
| 5-year return | +222.16% | -10.40% |
| P/E ratio (TTM) | 35.94 | 73.77 |
| Forward P/E | 31.69 | 26.18 |
| EPS (TTM) | $17.03 | $2.09 |
| Dividend yield | 0.00% | 0.18% |
| Annual dividend | $0.00 | $0.28 |
| Revenue (latest FY) | $2.53B | $2.86B |
| Revenue growth (YoY) | +19.97% | +3.67% |
| Net income (latest FY) | $451.12M | $241.20M |
| Operating margin | 21.14% | 12.49% |
| Net margin | 17.83% | 8.45% |
| 52-week high | $677.90 | $166.25 |
| 52-week low | $373.00 | $81.22 |
| Distance from 52-week high | -9.71% | -7.26% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -3.30% | -11.88% |
| Average volume | 272.38K | 1.79M |
| Shares outstanding | 27.91M | 111.59M |
| Employees | 6,500 | 11,000 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RVTY has outperformed MEDP by 52.3 percentage points over the past year.
- Revvity trades at a higher earnings multiple (73.8x vs 35.9x trailing P/E).
- Medpace is more profitable, keeping 17.8 cents of every revenue dollar as net income versus 8.4 cents for Revvity.
- Medpace grew revenue faster in its latest fiscal year (+19.97% vs +3.67%).
- The two companies sit in different sectors: Medpace in Health Care and Revvity in Industrials.
About Medpace
MEDP stock →Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 6,500 employees
About Revvity
RVTY stock →Revvity, Inc. provides health sciences solutions, technologies, and services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,000 employees
MEDP vs RVTY FAQ
Which is bigger, Medpace or Revvity?
Revvity (RVTY) is larger, with a market capitalization of $17.20B compared with $17.08B for Medpace (MEDP).
Which stock has performed better over the past year, MEDP or RVTY?
RVTY returned +65.81% over the past 12 months, compared with +13.50% for MEDP (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, MEDP or RVTY?
MEDP has the lower trailing P/E at 35.9, versus 73.8 for RVTY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Medpace or Revvity?
Revvity pays a dividend yielding 0.18%, while Medpace does not currently pay a regular dividend.
Are Medpace and Revvity in the same industry?
No. Medpace is in the Health Care sector, while Revvity is in Industrials.